The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?

• Published in: Blood advances Vol. 7; no. 11; pp. 2401 - 2417
• Main Authors: Gamal, Wael, Sahakian, Eva, Pinilla-Ibarz, Javier
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 13-06-2023; The American Society of Hematology
• Subjects: B-Lymphocytes; Cytokines - pharmacology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Review; Th17 Cells - pathology; Tumor Microenvironment
• ISSN: 2473-9529; 2473-9537; 2473-9537
• DOI: 10.1182/bloodadvances.2022008985

[Display omitted]
T helper 17 (Th17) cells have a prominent role in autoimmune diseases. In contrast, the nature of these cells in cancer is controversial, with either pro- or antitumorigenic activities depending on various cancer settings. Chronic lymphocytic leukemia (CLL), a B-cell malignancy, is characterized by an imbalance in T-cell immune responses that contributes to disease progression and increased mortality. Many clinical reports indicate an increase in Th17 cells and/or interleukin 17 serum cytokine levels in patients with CLL compared with healthy individuals, which correlates with various prognostic markers and significant changes in the tumor microenvironment. The exact mechanisms by which Th17 cells might contribute to CLL progression remain poorly investigated. In this review, we provide an updated presentation of the clinical information related to the significance of Th17 cells in CLL and their interaction with the complex leukemic microenvironment, including various mediators, immune cells, and nonimmune cells. We also address the available data regarding the effects of CLL-targeted therapies on Th17 cells and the potential of using these cells in adoptive cell therapies. Having a sound understanding of the role played by Th17 cells in CLL is crucial for designing novel therapies that can achieve immune homeostasis and maximize clinical benefits.